MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-30-2023
HTG Molecular Diagnostics Cost of Revenue 2011-2026 | HTGM
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue HTG Molecular Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.57 M | 4.09 M | 3.99 M | 8.91 M | 5.09 M | 4.97 M | 4.14 M | 3.34 M | 3.2 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.91 M | 3.2 M | 4.7 M |
Quarterly Cost of Revenue HTG Molecular Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 671 K | 1.01 M | 855 K | - | 984 K | 971 K | 785 K | - | 941 K | 975 K | 1.02 M | - | 2.94 M | 2.51 M | 2.05 M | - | 1.24 M | 1.45 M | 1.14 M | - | 1.09 M | 1.24 M | 1.3 M | - | 1.13 M | 933 K | 843 K | - | 809 K | 835 K | 895 K | - | 747 K | 616 K | 642 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.94 M | 616 K | 1.13 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
2.91 B | $ 114.87 | -0.65 % | $ 34.9 B |  USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
222 K | $ 1.63 | -1.21 % | $ 2.17 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 24.7 | -1.12 % | $ 686 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 21.91 | 0.27 % | $ 1.17 B | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 15.3 | -1.92 % | $ 463 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Guardant Health
GH
|
349 M | $ 83.09 | -6.11 % | $ 10.4 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 27.12 | -1.53 % | $ 20 B |  Niderland |
 |
Illumina
ILMN
|
1.51 B | $ 126.92 | -1.24 % | $ 20.2 B | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.93 | - | $ 8.54 M | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 83.55 | -0.67 % | $ 5.64 B | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
4.81 M | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 102.49 | -0.7 % | $ 8.45 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 259.57 | -1.47 % | $ 21.6 B | USA |
 |
NeoGenomics
NEO
|
413 M | $ 9.02 | 4.76 % | $ 1.16 B | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 9.34 | -1.16 % | $ 2.03 B | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.84 | 0.21 % | $ 448 M | USA |
 |
Natera
NTRA
|
158 M | $ 200.17 | -2.06 % | $ 19.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 195.05 | -0.8 % | $ 21.7 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
3.32 M | - | -16.95 % | $ 1.54 M | USA |
 |
Organovo Holdings
ONVO
|
5 K | - | -2.3 % | $ 19.4 M | USA |
 |
PerkinElmer
PKI
|
1.44 B | - | -0.91 % | $ 14.7 B | USA |
 |
Precipio
PRPO
|
13.3 M | $ 31.75 | 3.42 % | $ 51 M | USA |
 |
Personalis
PSNL
|
57.8 M | $ 5.5 | -7.72 % | $ 326 M | USA |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 7.18 | -1.24 % | $ 300 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 16.65 | -12.64 % | $ 179 M | China |